Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Metyrosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | EGFR | P00533 | 1/20 | 0.67 |
| ▸ | FYN | P06241 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | APEX1 | P27695 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metyrosine SCHEMBL5053839 | 1.00 | BLM (1.00) | BLMALDH1A1CYP3A4KDM4ECYP1A2 | |
| Metyrosine SCHEMBL162280 | 1.00 | BLM (1.00) | BLMALDH1A1CYP3A4KDM4ECYP1A2 | |
| Racemetyrosine SCHEMBL61871 | 1.00 | BLM (1.00) | BLMALDH1A1CYP3A4KDM4ECYP1A2 | |
| Metyrosine SCHEMBL3020472 | 0.98 | BLM (0.96) | BLMALDH1A1CYP3A4KDM4ECYP1A2 | |
| Metyrosine SCHEMBL27799143 | 0.98 | BLM (0.96) | BLMALDH1A1CYP3A4KDM4ECYP1A2 | |
| Metyrosine SCHEMBL29435134 | 0.98 | BLM (0.96) | BLMALDH1A1CYP3A4KDM4ECYP1A2 | |
| Metyrosine SCHEMBL6254539 | 0.98 | BLM (0.96) | BLMALDH1A1CYP3A4KDM4ECYP1A2 | |
| Racemetyrosine SCHEMBL28095637 | 0.95 | BLM (0.90) | BLMALDH1A1CYP3A4KDM4ECYP1A2 | |
| SCHEMBL24305563 | 0.85 | BLM (0.73) | BLMALDH1A1CYP3A4KDM4ECYP1A2 | |
| SCHEMBL6717498 | 0.85 | BLM (0.73) | BLMALDH1A1CYP3A4KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9003 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-12564596-B2 | Agents and methods for modulating pathogen activity | GRIFFITH UNIVERSITY (AU) | 2026-03-03 | — | — | US | claimed |
| US-12564622-B2 | Preventing cytokine release syndrome | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-03-03 | — | — | US | claimed |
| EP-3570864-B1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4658374-A1 | METHODS FOR PREPARING CRYSTALLINE PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Janssen Pharmaceutica NV (BE) | 2025-12-10 | — | — | EP | claimed |
| EP-4613761-A9 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | claimed |
| EP-4613761-A2 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2025-09-10 | — | — | EP | claimed |
| EP-4602049-A1 | SOS1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-08-20 | — | — | EP | claimed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | claimed |
| WO-1991005555-A2 | N-ACYL PEPTIDE METALLOENDOPEPTIDASE INHIBITORS AND METHODS OF USING SAME | THE SALK INSTITUTE BIOTECHNOLOGY/INDUSTRIAL ASSOCIATES, INC. (US) | 1991-05-02 | — | — | WO | claimed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | claimed |
| EP-0036713-B1 | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | UNIVERSITY OF MIAMI (US) | 1984-01-18 | — | — | EP | claimed |
| US-4389415-A | ALPHA-METHYL-P-TYROSINE, HYDRAZINO PHENYLPROPIONIC ACID | MERCK & CO., INC. (US) | 1983-06-21 | — | — | US | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |
| US-4230883-A | REACTION OF CORRESPONDING AMINO ACID WITH HCL OR HBR IN THE ABSENCE OF A SOLVENT | MERCK & CO., INC. (US) | 1980-10-28 | — | — | US | claimed |
| US-4165382-A | Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine | POZUELO JOSE | 1979-08-21 | — | — | US | claimed |
| EP-0003353-A1 | A pharmaceutical composition for oral administration for treating hypertension | MERCK & CO. INC. (US) | 1979-08-08 | — | — | EP | claimed |
| US-4117161-A | METHOD OF PHARMACOLOGICALLY TREATING DRUG ADDICTION WITH ALPHA-METHYL-PARA-TYROSINE | POZUELO JOSE | 1978-09-26 | — | — | US | claimed |